Short-term Intravenous Iron Isomaltose Anhydride for IDA
ConditionIron Deficiency Anemia
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age14-99
SponsorWest China Hospital
About this trial
This prospective, randomized, controlled study aims to evaluate the impact of short-term intravenous iron isomaltose anhydride on postoperative recovery and the requirement for allogeneic red blood cells (RBC) transfusion in preoperative Iron-deficiency anemia (IDA) patients receiving orthopedic surgery, thus facilitating developing a simple and effective iron supplement approach for patients' recovery.
Eligibility criteria
Qualifiers
Age > 14 years;
Sign and date the "informed consent form"
Disqualifiers
Pregnant or lactation;
Drug abuse, including but not limited to opioids, amphetamines, ice, ketamine, etc.;
History of anaphylaxis to oral or intravenous iron;
Nervous system diseases such as peripheral neuropathy, mental illness;
Trial design
Treatments tested in this trial
- Intravenous iron isomaltose anhydride
Treatment groups
1,600 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov